In our study, the adverse effect of high expression levels of ACTN1 and ACTN3 was not observed in the allo-HSCT group, suggesting that allo-HSCT might surmount the adverse effect of ACTN1 and ACTN3 overexpression in AML patients. The gene discussed is ACTN1; the disease is acute myeloid leukemia.